Comparison of renal changes with lopinavir/ritonavir plus raltegravir or tenofovir/emtricitabine in the PROGRESS study. (August 2014)

• Record Type: Journal Article
• Authors: Girard, Pierre-Marie; Cotte, Laurent; Gathe, Joseph; Renjifo, Boris; Argyropoulos, Christos; Trinh, Roger; Fredrick, Linda M; Norton, Michael; Nilius, Angela
• Is Part Of: Future virology. Volume 9:Number 8(2014)
• Page Start: 707
• Page End: 714
• Publication Date: 2014-08
• Subjects: antiretroviral -- HIV infection -- lopinavir/r -- raltegravir -- renal -- tenofovir; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl.14.55
• Languages: English
• ISSNs: 1746-0794

Abstract

ABSTRACT : Aim: To assess renal function changes among 172 treatment-naive subjects treated with lopinavir/ritonavir (LPV/r) plus raltegravir (RAL) or LPV/r plus tenofovir/emtricitabine in the PROGRESS study, a prospective, randomized controlled trial.Patients & methods: Serum creatinine, creatinine clearance and chronic kidney disease category were compared between groups.Results: Mean change from baseline to week 96 in creatinine clearance was smaller with LPV/r plus RAL versus LPV/r plus tenofovir/emtricitabine (-1.4 vs -7.3 ml/min; p = 0.035). Chronic kidney disease category improvement was more frequent and the mean increase in serum creatinine was smaller for the LPV/r plus RAL group. Differences in estimated renal function were also detected when the analysis was performed according to baseline demographics.Conclusion: Smaller renal function declines were observed with LPV/r plus RAL. The results from this study warrant further evaluation of the renal safety profile of nucleotide reverse transcriptase inhibitor-sparing regimens.